|
Synonyms: CL-2C | NVP-QGE031 | QGE031
Compound class:
Antibody
Comment: Ligelizumab is a humanized, investigational high-affinity anti-IgE monoclonal antibody with anti-inflammatory potential [1], with improved pharmacokinetics and clinical effects compared to omalizumab.
Peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide sequence analysis reveals identical matches with antibody sequences claimed in patent US7531169 B2, where it is the clone designated as CL-2C [3]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Several Phase 2 clinical trials were underway to evaluate the potential of QGE031 as a treatment for asthma and chronic spontaneous urticaria [2]. As of May 2021, the asthma studies had been terminated, duw to alck of efficacy. Ligelizumab failed to demonstrate superiority over placebo or omalizumab [4]. Evaluation in chronic urticaria has progressed to Phase 3. |
| Mechanism Of Action and Pharmacodynamic Effects |
| IgE acts as an environmental sensor facilitating an immune response via the high-affinity IgE receptor, FcεRI. This action sensitizes mast cells to specific antigens which, upon allergen exposure, release pro-inflammatory cytokines and other mediators of the allergic response. Ligelizumab is designed to bind to circulating IgE, thereby reducing IgE-mediated responses. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01716754 | Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma | Phase 2 Interventional | Novartis | 4 | |
| NCT03907878 | A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines | Phase 3 Interventional | Novartis | ||
| NCT04210843 | Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab | Phase 3 Interventional | Novartis | ||
